Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Prognostic factors and outcome of surgically treated patients with brain metastases of non-small cell lung cancer.

Tytuł:
Prognostic factors and outcome of surgically treated patients with brain metastases of non-small cell lung cancer.
Autorzy:
She C; Department of Neurosurgery and Neuro-Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Wang R; Department of Neurology, The Second Hospital of Tianjin Medical University, Tianjin, China.
Lu C; Ultrasound Department, Binzhou People's Hospital, Binzhou, China.
Sun Z; Department of Neurosurgery and Neuro-Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Li P; Department of Neurosurgery and Neuro-Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Yin Q; Department of Neurosurgery and Neuro-Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Liu Q; Department of Neurosurgery and Neuro-Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Wang P; Department of Neurosurgery and Neuro-Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Li W; Department of Neurosurgery and Neuro-Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Źródło:
Thoracic cancer [Thorac Cancer] 2019 Feb; Vol. 10 (2), pp. 137-142. Date of Electronic Publication: 2018 Nov 28.
Typ publikacji:
Clinical Trial; Journal Article
Język:
English
Imprint Name(s):
Publication: November 2012- : Singapore : Tianjin : Wiley Publishing Asia Pty Ltd ; Tianjin Lung Cancer Institute
Original Publication: Richmond, Vic. : Tianjin : Blackwell Pub. Asia Pty Ltd. ; Tianjin Lung Cancer Institute
MeSH Terms:
Adenocarcinoma of Lung/*mortality
Brain Neoplasms/*mortality
Carcinoma, Non-Small-Cell Lung/*mortality
Carcinoma, Squamous Cell/*mortality
Lung Neoplasms/*mortality
Pneumonectomy/*mortality
Adenocarcinoma of Lung/pathology ; Adenocarcinoma of Lung/surgery ; Adult ; Aged ; Aged, 80 and over ; Brain Neoplasms/secondary ; Brain Neoplasms/surgery ; Carcinoma, Non-Small-Cell Lung/pathology ; Carcinoma, Non-Small-Cell Lung/surgery ; Carcinoma, Squamous Cell/pathology ; Carcinoma, Squamous Cell/surgery ; Female ; Follow-Up Studies ; Humans ; Lung Neoplasms/pathology ; Lung Neoplasms/surgery ; Male ; Middle Aged ; Prognosis ; Retrospective Studies ; Survival Rate
References:
N Engl J Med. 1990 Feb 22;322(8):494-500. (PMID: 2405271)
Arq Neuropsiquiatr. 2004 Sep;62(3B):808-14. (PMID: 15476074)
Surg Neurol Int. 2017 Oct 24;8:259. (PMID: 29184710)
J Neurosurg. 1993 Aug;79(2):210-6. (PMID: 8331402)
J Neurosurg. 2001 Oct;95(4):595-600. (PMID: 11596953)
Curr Oncol Rep. 2011 Aug;13(4):255-8. (PMID: 21584645)
Lung Cancer. 2013 Nov;82(2):319-23. (PMID: 24018025)
Brain Tumor Res Treat. 2013 Oct;1(2):64-70. (PMID: 24904894)
Cancer. 1997 Sep 1;80(5):1002-4. (PMID: 9307209)
Clin Exp Metastasis. 2015 Feb;32(2):143-9. (PMID: 25628027)
J Clin Neurosci. 2013 Jun;20(6):771-5. (PMID: 23632290)
Clin Exp Metastasis. 2013 Aug;30(6):723-9. (PMID: 23392634)
Int J Radiat Oncol Biol Phys. 2000 Jan 15;46(2):297-302. (PMID: 10661335)
CA Cancer J Clin. 2011 Mar-Apr;61(2):91-112. (PMID: 21303969)
Cancer. 1965 Mar;18:298-306. (PMID: 14264031)
J Neurol Neurosurg Psychiatry. 1994 Aug;57(8):950-6. (PMID: 8057119)
J Clin Oncol. 1993 Feb;11(2):369-73. (PMID: 8426215)
Int J Radiat Oncol Biol Phys. 1997 Mar 1;37(4):745-51. (PMID: 9128946)
Am J Roentgenol Radium Ther Nucl Med. 1971 Feb;111(2):334-6. (PMID: 5541678)
Nat Rev Clin Oncol. 2011 Dec 06;9(2):79-86. (PMID: 22143137)
Cancer. 2018 May 15;124(10):2072-2074. (PMID: 29603127)
Ann Thorac Surg. 1986 Oct;42(4):360-4. (PMID: 3767508)
CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32. (PMID: 26808342)
Chin Clin Oncol. 2017 Aug;6(4):35. (PMID: 28841797)
J Clin Oncol. 1988 Sep;6(9):1474-80. (PMID: 3047337)
Cancer. 2010 Nov 1;116(21):5038-46. (PMID: 20629035)
Proc Am Thorac Soc. 2011 Sep;8(5):381-5. (PMID: 21926387)
Contributed Indexing:
Keywords: Brain metastases; non-small cell lung cancer (NSCLC); prognostic factor; recursive partitioning analysis (RPA)
Entry Date(s):
Date Created: 20181129 Date Completed: 20200207 Latest Revision: 20200309
Update Code:
20240105
PubMed Central ID:
PMC6360214
DOI:
10.1111/1759-7714.12913
PMID:
30485664
Czasopismo naukowe
Background: Brain metastases (BM) are a common consequence of lung cancer and surgery is effective; however, the factors affecting survival after surgery are unclear. The aim of this study was to identify the outcomes and prognoses of post-metastasectomy patients with BM from non-small cell lung cancer (NSCLC) at a single institution over a 15-year period.
Methods: NSCLC patients who had undergone BM surgery were retrospectively identified. Survival was analyzed using the Kaplan-Meier curve, and univariate and multivariate factors associated with survival were identified using the Cox proportional hazards model.
Results: The median overall survival was 9.8 months, 18 (14.8%) patients survived > 24 months, and 6 (4.9%) > 36 months. The one and two-year survival rates were 41% and 18.6%, respectively. Univariate analysis revealed that recursive partitioning analysis (RPA) classification, Karnofsky Performance Scale (KPS) scores, BM number, extracranial metastasis status, different lesion locations, resection extent, postoperative treatment, and salvage therapy after recurrence significantly influenced patient survival. The different treatment modalities for primary lesions also affected postoperative survival. KPS ≥ 70, RPA class I/II, and postoperative chemotherapy were independent factors that decreased the risk of death from BM. Interestingly, the initial onset of intracranial lesions could increase the risk of death from BM.
Conclusion: A KPS score ≥ 70, RPA class I/II, and postoperative chemotherapy could benefit post-metastasectomy patients with BM from NSCLC. Conversely, the initial onset of intracranial lesions is an unfavorable factor that increases the risk of death. These findings support the use of personalized therapy for patients with BM from NSCLC.
(© 2018 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.)
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies